Corporate GovernanceJun 24, 2026, 04:52 PM
Revelation Biosciences Amends CEO/CFO Employment Agreements
AI Summary
Revelation Biosciences, Inc. amended executive employment agreements for its CEO, James Rolke, and CFO, Chester S. Zygmont, III, effective June 24, 2026. These amendments include increased change-in-control severance benefits, greater flexibility for outside activities, and a three-year initial term with automatic renewals. Concurrently, the company's Board approved amendments to its bylaws, incorporating universal proxy rules for director nominations and formally defining "Cause" for directors and officers.
Key Highlights
- CEO/CFO change-in-control severance increased to 2x salary + target bonus.
- CEO/CFO to receive up to 18 months of COBRA premium reimbursement.
- CEO/CFO gain flexibility for beneficial outside activities.
- CEO/CFO employment agreements have 3-year initial term.
- Bylaws amended for Universal Proxy Rules (Rule 14a-19).
- New bylaw requires 120-day advance notice for director nominees.
- Bylaws now formally define "Cause" for directors/officers.
Price Impact
More from REVB